Docetaxel - Starpharma

Drug Profile

Docetaxel - Starpharma

Alternative Names: Dendrimer docetaxel; DEP™-Docetaxel; DTX-SPL8783

Latest Information Update: 28 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Starpharma
  • Developer Monash University; Starpharma
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 28 Nov 2017 Phase-II clinical trials in Non-small cell lung cancer (Combination therapy) in United Kingdom (IV) (EudraCT2016-000877-19)
  • 28 Nov 2017 Phase-II clinical trials in Solid tumours (Late-stage disease, Monotherapy) in United Kingdom (IV) (EudraCT2016-000877-19)
  • 26 Oct 2017 Adverse events data from the phase I portion of a phase I/II trial in Non-small cell lung cancer and Solid tumours released by Starpharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top